General Product Information: All three cancer associated antigens are supplied in phosphate buffered saline, pH 7.4 ± 0.2, containing 0.1% sodium azide as a preservative. CAA-Pancreatic is isolated from human fluids, CAA-Breast is isolated from cell culture, and CAA-Ovarian is isolated from human fluids or cell culture. In general the cell culture isolated material is more readily available than the human fluid sourced material.
Catalog No. C1824 (Part No. 90295) - ovarian
High Purity - report known contaminants and method.
Report concentration (U/ml) and method. Report A280.
Sample Certificate, MS Word
Catalog No. C1824 (Part No. 90420) - ovarian, cell culture
High Purity - report known contaminants and method.
Report concentration (U/ml) and method. Report A280.
Sample Certificate, MS Word
Catalog No. C1924 (Part No. 90352) - breast, cell culture
Report known contaminants and method.
Report concentration (U/ml) and method. Report A280.
Sample Certificate, MS Word
Catalog No. C2023 (Part No. 90399) - pancreatic, part pure
Part Pure - contaminants have not been determined.
Report concentration (U/ml) and method. Report A280.
Sample Certificate, MS Word
Catalog No. C2024 (Part No. 90102) - pancreatic
High Purity - report known contaminants and method.
Report concentration (U/ml) and method. Report A280.
Sample Certificate, MS Word
Cancer Associated Antigen - Breast (CAA-B) originated from a primary breast cancer cell colony. It is a glycoprotein of molecular weight 330,000 - 450,000. Studies suggest it is 50% carbohydrate, linked through an O-glycosidic bond to the polypeptide backbone. Clinically, CAA-B is elevated in the serum of patients with mammary tumors. Immunoassays for CAA-B are not recommended to screen for breast cancer, but show significant clinical utility in the post-surgical follow-up of breast cancer patients.
Cancer Associated Antigen - Ovarian (CAA-O) is part of a high molecular weight glycoprotein complex found in the serum of women with epithelial ovarian cancer. The CAA-O complex, although not completely defined, has a molecular weight of approximately 200,000. It is 24% carbohydrate, with mannose as the main sugar component. Difficult to diagnose, ovarian cancer has become one of the most lethal forms of gynecological malignancies in the United States. One of the most promising applications of CAA-O immunoassays relates to the discrimination between benign and malignant pelvic masses at the time of initial diagnosis. Furthermore, serum levels of CAA-O and CEA may be useful in differentiating between ovarian and non-ovarian malignant diseases.
Cancer Associated Antigen - Pancreatic (CAA-P) is an antigenic determinant associated with a 210,000 Da glycoprotein detected in the serum and ascites fluid of cancer patients. This glycoprotein is acidic in nature due to the high sialic acid content and has a large amount of serine, threonine, and acidic or amide amino acids. In addition, it contains no detectable cysteine. While the clinical diagnosis of pancreatic cancer is difficult because symptoms are non-specific and ill-defined, CAA-P is, to date, the most reliable, non-invasive, and inexpensive serum marker developed to monitor the progression of pancreatic cancer, allowing the differentiation between pancreatic cancer and chronic pancreatitis. It should be noted, however, that the clinical serum assay for CAA-P is not intended as an initial screen for pancreatic cancer; it is recommended for post-surgical follow-up only.